Bona fide disclosure requirements govern under-reporting penalties, and post-penalty immunity applications cannot secure available statutory protectio...
Certificate-of-origin verification procedure governs preferential customs benefits; denial without retroactive verification was set aside with consequ...
Disciplinary Committee jurisdiction and mandatory investigation requirements invalidated cancellation of an insolvency professional's registration and...
Bulk drugs and active pharmaceutical ingredients imported under Chapters 28 or 29 qualify as drugs because they are substances used as components of pharmaceutical products. The specific description-based IGST entry for drugs and medicines under Sl. No. 226 of Schedule I to Notification No. 9/2025-Integrated Tax (Rate) applies to goods falling under Chapter 30 or any other chapter. This specific entry prevails over the general chapter-based entries for inorganic and organic chemicals. Imports for testing or research do not alter an API's character as a drug. IGST is chargeable at 5%, unless the goods fall within the nil-rated entry for drugs or medicines listed in Annexure I.
Bulk drugs and active pharmaceutical ingredients imported under Chapters 28 or 29 qualify as drugs because they are substances used as components of pharmaceutical products. The specific description-based IGST entry for drugs and medicines under Sl. No. 226 of Schedule I to Notification No. 9/2025-Integrated Tax (Rate) applies to goods falling under Chapter 30 or any other chapter. This specific entry prevails over the general chapter-based entries for inorganic and organic chemicals. Imports for testing or research do not alter an API's character as a drug. IGST is chargeable at 5%, unless the goods fall within the nil-rated entry for drugs or medicines listed in Annexure I.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
of 4805
Join Channel
TaxTMI 
